Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,591.90
(
0.54%
)
US TECH 100
23,455.54
(
0.41%
)
Dow Jones
46,429.49
(
0.66%
)
Brent Oil
98.78
(
2.36%
)
Bitcoin
71,370.01
(
1.21%
)
News Focus
News Focus
Post# of 257286
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122810
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: gofishmarko post# 38229

Wednesday, 11/29/2006 4:21:10 PM

Wednesday, November 29, 2006 4:21:10 PM

Post# of 257286
DVAX – Despite the deficiency in IP, DVAX may be able to exploit the rivalry between GSK and MRK to get one of them to bid for the rights to Heplisav. Whichever company does not deal with DVAX could end up with no market in due course. Of course, the numbers at risk are pretty small for companies the size of GSK and MRK, so they could opt to do nothing.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today